Subscribe to Search results

An internal DHSS minute, referring to Armour's letter to haemophilia centre directors withdrawing batches of Factorate which had not been donor screened, stated that Rorer Health Care Ltd claimed to be in compliance with their product licence and that the matter had not been treated as a product defect.

Published on:

A memo from Dr Harris to Dr Smithies attached a letter that was sent to all haemophilia centre directors confirming the availability of heated Factor 8 concentrates and advising that there was therefore no longer any need to use un-heat-treated Factor VIII concentrate.

Published on:

In a memo from Dr Walford to Dr Fowler, Dr Walford flagged that Travenol (Hyland) were planning a symposium in early 1983 to launch a reduced hepatitis risk product.

Published on:

In a minute from D O Hagger to Mr O'Connor, it was decided that, in light of recent seroconversion cases, if Armour did not agree to a voluntary withdrawal the DHSS would need to consider the case further as to what their course of action should be.

Published on:

Dr Hill, of Birmingham Children's Hospital, wrote to the Department of Health stating his belief that there had been three definite cases and one probable case of seroconversion amongst his patients.

Published on:

In a memo from Dr Isaacs to Dr Rotblat, Dr Isaacs attached a letter received from Peter Jones in which he suggested taking action against the Armour material.

Published on:

An editorial in the "British Medical Journal" asserted that the protein fractionation centres lacked sufficient staff, accommodation, equipment and the basic organisational units to do the job.

Published on:

In a letter from Dr Biggs to Dr Godber, she called attention to the lack of organisation, apparatus and buildings needed in order to produce Factor 8.

Published on:

In the minutes of an AIDS group of haemophilia centre directors' meeting, Dr Mortimer told the meeting that he was concerned to see that a large number of centres were still using non-heat-treated Factor 8, and suggested that all directors should be advised not to use it.

Published on:

During a meeting of the AIDS group of haemophilia centre directors, directors were recommended to use only heat-treated products now these were available.

Published on:

At a UKHCDO Hepatitis Working Party meeting Dr Craske identified eight patients treated with (unheated) Factor 9 who had seroconverted.

Published on:

Haemofact No 6 reported that Lord Glenarthur, Parliamentary Under-Secretary of State for Health, speaking in the House of Lords, had made it clear that all home produced Factor 8 would be heat treated from April 1985.

Published on:

The "Daily Mail" published a front page article with the headline "AIDS Virus kills man in Britain".

Published on:

The "Daily Express" published an article titled "Twin bid to curb killer AIDS peril".

Published on:

"The Times" published an article titled "Treated blood cuts Aids risk to haemophiliacs".

Published on:

Douglas Starr, in his book "An Epic History of Medicine and Commerce" commented: "Once AIDS became an acknowledged reality, the drug firms quickly developed screening tests and virus-killing technologies...If they had heeded the warnings of Factor VIII...they would have abandoned the high-risk collection centres sooner and worked more intensively on virus-killing technology."

Published on:

Professor Titmuss published his book "The Gift Relationship".

Published on:

The use of genetically engineered blood clotting agents was announced in October 1988 at the Royal Free Hospital.

Published on:

At a Haemophilia Society Executive Committee meeting it was reported that "the introduction of heat-treated materials has been 'patchy' and that at least one Supra-Region had not yet introduced heat-treated materials."

Published on:

Dr Denis Donohue of the FDA asked the pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to hepatitis.

Published on: